Reproductive · PANCE / PANRE

Intrauterine Growth Restriction (IUGR)

Fetal growth below the 10th percentile for gestational age due to a pathologic process.

Also known as: IUGR, FGR, fetal growth restriction, small for gestational age, SGA

Overview

Fetal growth restriction (now the preferred term, FGR) is defined by ACOG/SMFM as estimated fetal weight or abdominal circumference below the 10th percentile for gestational age. SGA refers to a constitutionally small but otherwise healthy fetus; IUGR/FGR implies a pathologic process limiting growth.

Epidemiology

Affects 3-10% of pregnancies. Strongly associated with stillbirth, perinatal morbidity, and long-term cardiometabolic and neurodevelopmental disease (Barker hypothesis).

🔒 Free preview limit reached

Keep reading — start your free trial

You've read your 2 free diagnosis previews. Create your free account to unlock the full Intrauterine Growth Restriction (IUGR) outline — plus all 514 diagnoses, 3,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.

Free to start · No credit card · Cancel anytime

Risk factors

  • Maternal: hypertensive disorders (chronic HTN, preeclampsia), pregestational diabetes with vasculopathy, autoimmune (APS, SLE), severe anemia, malnutrition, low pre-pregnancy BMI, cyanotic cardiac disease
  • Behavioral: smoking, alcohol, cocaine, opioid use
  • Placental: placental insufficiency, abruption, infarction, single umbilical artery, velamentous insertion
  • Fetal: aneuploidy (trisomy 13, 18, 21, Turner), congenital malformation, multiple gestation, congenital infection (TORCH — toxoplasmosis, CMV, rubella, syphilis, varicella)

Pathophysiology

Symmetric IUGR (proportional reduction of head and body) typically reflects an early-pregnancy insult — chromosomal abnormality or infection. Asymmetric IUGR (head sparing, with disproportionately small abdomen) reflects later-pregnancy uteroplacental insufficiency, with preferential blood flow to brain at the expense of the liver and subcutaneous tissue.

Clinical presentation

Symptoms

  • Often asymptomatic; detected on screening
  • Decreased fetal movement may indicate fetal compromise

Signs / physical exam

  • Fundal height lagging >=3 cm behind gestational age
  • Low maternal weight gain
  • Findings of associated maternal disease (e.g., hypertension)

Differential diagnosis

  • Constitutionally small (SGA) — Normal growth velocity on serial scans, normal Doppler studies, no risk factors; family history of small but healthy infants
  • Inaccurate dating — LMP unreliable; recheck with first-trimester crown-rump length (most accurate)
  • Oligohydramnios alone — Low AFI without growth lag — consider PROM, urinary tract anomaly

Diagnostic workup

Diagnostic criteria

Delphi consensus: EFW or AC <3rd percentile alone, OR EFW <10th percentile combined with abnormal Doppler indices or low growth velocity.

Labs

  • Targeted maternal evaluation: CMP, urine protein/creatinine ratio (preeclampsia), antiphospholipid antibodies if recurrent
  • TORCH serologies if early-onset, symmetric, or with anomalies
  • Aneuploidy screening / diagnostic testing per indication (cell-free DNA, amniocentesis, microarray)

Imaging

  • Ultrasound biometry: biparietal diameter, head circumference, abdominal circumference, femur length — EFW <10th percentile
  • Amniotic fluid index or single deepest pocket
  • Umbilical artery Doppler velocimetry — cornerstone of surveillance in FGR; assess for increased resistance, absent end-diastolic flow (AEDF), or reversed end-diastolic flow (REDF)
  • Middle cerebral artery (MCA) Doppler and ductus venosus Doppler in advanced or early-onset disease
  • Detailed anatomy scan to evaluate for structural anomalies

Diagnostic algorithm

PatternTiming of InsultTypical EtiologyHead:Abdomen Ratio
SymmetricEarly (1st-early 2nd trimester)Aneuploidy, TORCH infection, teratogenNormal (proportional)
AsymmetricLate (late 2nd-3rd trimester)Placental insufficiency, maternal HTN/PECIncreased (head sparing)
Symmetric vs asymmetric IUGR patterns.

Treatment

First-line

  • Identify and treat reversible causes (smoking cessation, BP control, anticoagulation for APS)
  • Antepartum surveillance: weekly to twice-weekly NSTs and/or BPPs, growth ultrasound every 2-4 weeks, serial umbilical artery Dopplers
  • Antenatal corticosteroids if delivery anticipated 24 0/7 to 33 6/7 wk (consider 34 0/7 to 36 6/7 wk per ACOG)
  • Magnesium sulfate for neuroprotection if delivery <32 wk

Delivery timing (SMFM/ACOG)

  • Isolated FGR with normal Dopplers: 36 0/7 to 37 6/7 wk
  • FGR with comorbid condition or oligohydramnios: 34 0/7 to 37 6/7 wk
  • FGR with absent end-diastolic flow: 34 0/7 wk
  • FGR with reversed end-diastolic flow: 30 0/7 wk
  • Any FGR with abnormal BPP or fetal compromise: deliver

Second-line / adjunct

  • Low-dose aspirin (81 mg daily, started ideally <16 wk) for women at high risk of preeclampsia/placental insufficiency
  • Mode of delivery individualized — cesarean preferred for REDF or non-reassuring monitoring; vaginal delivery acceptable in many cases with continuous monitoring

Complications

  • Stillbirth (risk increases with severity and abnormal Dopplers)
  • Neonatal hypoxia, meconium aspiration, hypoglycemia, hypothermia, polycythemia, hypocalcemia
  • Long-term: neurodevelopmental impairment, hypertension, insulin resistance, cardiovascular disease (DOHaD/Barker hypothesis)

PANCE pearls

  • Absent or reversed end-diastolic flow on umbilical artery Doppler are markers of severe placental insufficiency requiring escalation of care and consideration of delivery.
  • Symmetric IUGR raises concern for early insult — order TORCH and consider aneuploidy testing.
  • Always re-verify dating before diagnosing IUGR — first-trimester ultrasound is the gold standard.
  • Aspirin 81 mg from 12-16 wk reduces preeclampsia and may reduce FGR in high-risk patients (USPSTF Grade A).
  • FGR is not the same as SGA — about 70% of fetuses with EFW <10th percentile are constitutionally small and healthy.

References

  • ACOG PB 227 — ACOG Practice Bulletin 227: Fetal Growth Restriction (Obstet Gynecol 2021)
  • SMFM Consult #52 — SMFM Consult Series #52: Diagnosis and Management of FGR (Am J Obstet Gynecol 2020)
  • USPSTF 2021 — USPSTF Grade A: Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality
  • TRUFFLE — Lees et al., Lancet 2015 — Ductus venosus Doppler vs CTG-guided delivery timing in early FGR

Practice Reproductive questions on FirstPassPA

Turn this outline into retention. 3,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.

Start studying free → Browse all 514 diagnoses

Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants.